🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Was reading through this fantastic piece 10.1016/j.ejca.2023.113357 by Alexander Sherry Pavlos Msaouel Ethan Ludmir MD I love this section specifically - keeping in mind the noncollapsibility in the context of odds ratio or hazard ratio. I learn everyday from these folks!

PLATO ACT 4: Ph II RCT of 50.4 vs. 41.4 Gy for T1-2 (<4 cm) N0 anal SCC. No difference in 3-year local recurrence (primary endpoint) or OS, & better toxicity/QOL with dose-reduction. Should 41.4 Gy be a SOC option (ahead of Ph III DECREASE trial reporting)? #ESTRO25

Deeply saddened that the entire team NCI Cancer Control National Cancer Institute PDQ Cancer Information has been eliminated. Our evidence-based summaries were updated throughout the year with the latest evidence and supported informed decision making between clinicians & patients across the US. 🇺🇸

Appreciate Significance making the primer on randomized non-comparative trials (RNCTs) freely available help to raise awareness of this phenomenon: academic.oup.com/jrssig/article… Frank Harrell Miguel Hernán Richard Riley (R²) Sander Greenland Andrew Vickers Ethan Ludmir MD Alexander Sherry

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!) PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.

The most underrated career skill is the ability to receive tough love. Acquiring knowledge is easy. Obtaining constructive criticism is hard. If you can't handle the truth, people stop telling you the truth. The people who grow the most are the ones who take feedback the best.

Dr Amol Akhade OS not statistically significant per p<0.05 definition but that’s clinical very significant. Interestingly, it is rather similar to how the FLOT arm did in ESOPEC

Krishan Jethwa Dr Amol Akhade Exactly! This is the classical large p-value misinterpretation M. Bolton

‼️ TAUTEM Phase 3 RCT T2-3bN0M0 rectal cancer -> chemoradiation and transanal excision vs TME DFS in both groups was 88.9%! Win for organ preservation and patients! jamanetwork.com/journals/jamas…

Matt Spraker Ours is this one!! Reena Engineer ascopubs.org/doi/10.1200/JC…

🙌CHECKMATE 8HW, long term outcomes🙌 🔍dMMR mCRC ✅Ipi+ Nivo continues to demonstrate substantially improved PFS compared with chemo ✅Plateuing of PFS curve… suggesting potential durability of M1 dz? ✅Ipi + Nivo > Nivo alone #ASCO25

🧵1/ Big news in unresectable stage III NSCLC. The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT). Early results are promising. Let’s dig in. 🔍 #LungCancer #RadOnc #ASCO25

🚨CM-577, long term🚨 Resected E/GEJ cancer s/p neoadjuvant CRT + surgery; path residual disease: 🔍Randomized: 12 m nivolumab vs. Surveillance Nivo demonstrated: ✅⬆️DFS ✅⬆️DMFS ✅⬆️OS 🔥PDL1>1 and Esophagus location > benefit 🧐Don’t be fooled be p=0.1 for OS. Study

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No

🚨SPRING-01🚨 🔍Locally Advanced Rectal Cancer RCT: 25 Gy x 5 ➡️ CAPOX +- Sintilimab 🔥+ Sintilimab demonstrated: ✅⬆️pCR 59% vs 33% ✅No significant adverse surgical or safety signals Time to explore with organ preserving approaches⁉️ #ASCO25

x.com/i/article/1929…

Hallucination isn't a bug, it's the essence of a model

What happens when you query chatGPT with 362 breast cancer cases? -46% responses differed from breast cancer expert opinion -when the same case was entered 3 times, the responses differed ~2/3 of the time ! -for examples, see 🧵..

🚨Study activated! NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100) Here's a short (7 min) video. Please consider enrolling & reach out w any q's. Thanks to the NIH, NCI, NRG Oncology for supporting our work! clinicaltrials.gov/study/NCT06958… 🙏🙏🙏

This will grab headlines but they used the ChatGPT 4 model which is for basic reasoning, which I would not consider tumor board to fit this. The o3 model actually reasons and would be at least a fighting chance. I have put it to the test with very complex scenarios with